



















8. Shukkoor AA, George NE, Radhakrishnan S, et al. Clinical characteristics and outcomes of patients admitted with acute heart failure: insights from a single-center heart failure registry in South India. *Egypt Heart J* 73 (2021): 38.
9. Bozkurt B, Coats AJ, Tsutsui H, et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. *J Card Fail* (2021): S1071-9164.
10. Westphal JG, Bekfani T, Schulze PC. What's new in heart failure therapy 2018? *Interact Cardio Vasc Thorac Surg* 27 (2018): 921-930.
11. Pereira-Barretto AC. Addressing Major Unmet Needs in Patients with Systolic Heart Failure: The Role of Ivabradine. *Am J Cardiovasc Drugs* 16 (2016): 93-101.
12. McDonagh TA, Metra M, Adamo M, et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 42 (2021): 3599-3726
13. Joshi SS, Singh T, Newby DE. Sodium-glucose cotransporter 2 inhibitor therapy: mechanisms of action in heart failure. *Heart* 107 (2021): 1032-1038.
14. Gormley L. Poll Results: SGLT2 Inhibitors for Patients with Heart Failure with Reduced Ejection Fraction: Who Should Prescribe Them? *American College of Cardiology* (2020).
15. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med* 373 (2015): 2117-2128
16. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *N Engl J Med* 377 (2017): 644-657.
17. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med* 380 (2019): 347-357.
18. Lopaschuk GD, Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. *JACC Basic Transl Sci* 5 (2020): 632-644.
19. Verma S. Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits. *Am J Cardiol* 124 (2019): S36-44.
20. Xiang B, Zhao X, Zhou X. Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients. *Cardiovasc Diabetol* 20 (2021): 78
21. Rabizadeh S, Nakhjavani M, Esteghamati A. Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review. *Int J Endocrinol Metab* 17 (2019): e84353.
22. Staels B. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. *Am J Cardiol* 120 (2017): S28-36.
23. Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. *Nat Rev Cardiol* 17 (2020): 761-772.
24. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. *Diabetologia* 61 (2018): 2108-2117.
25. Li X, Zhang Q, Zhu L, et al. Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure: A meta-analysis of randomized controlled trials. *Int J Cardiol* 332 (2021): 119-126.
26. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med* 381 (2019): 1995-2008.
27. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. *N Engl J Med* 384 (2021): 117-128.
28. Packer M, Anker SD, Butler J. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. *N Engl J Med* 383 (2020): 1413-1424.
29. Zannad F, Ferreira JP, Pocock SJ. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. *Lancet* 396 (2020): 819-829
30. Curtain JP, Docherty KF, Jhund PS, et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. *Eur Heart J* 27 (2021): ehab560.
31. Butler J, Usman MS, Khan MS, et al. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. *ESC Heart Fail* 7 (2020): 3298-3309.
32. Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. *N Engl J Med* 383 (2020): 1425-1435.
33. Palmiero G, Cesaro A, Vetrano E, et al. Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects. *Int J Mol Sci* 22 (2021): 5863.
34. Genuardi MV, Mather PJ. The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction. *Ther Adv Cardiovasc Dis* 15 (2021): 17539447211002678.

35. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med* 383 (2021): 1436-1446.
36. Starr JA, Pinner NA, Lisenby KM, et al. Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction. *Pharmacotherapy* 41 (2021): 526-536.
37. Yan Y, Liu B, Du J, et al. SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis. *ESC Heart Fail* 8 (2021): 2210-2219.
38. McMurray JJV, Packer M. How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?: A Redefinition of Evidence-Based Medicine. *Circulation* 143 (2021): 875-877.
39. Greene SJ, Butler J, Fonarow GC. Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure—Optimizing Therapy With the Need for Speed. *JAMA Cardiol* 6 (2021): 743-744.
40. Rosano GMC, Moura B, Metra M, et al. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 23 (2021): 872-881.
41. Liu PP. Cardiorenal syndrome in heart failure: a cardiologist's perspective. *Can J Cardiol* 24 (2008): 25B–9B.
42. Fontes-Carvalho R, Santos-Ferreira D, Raz I, et al. Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin. *Eur J PrevCardiol* (2021).
43. Sultan AB, Barone S, Kumar S. REVEAL-CKD: Prevalence of and Patient Characteristics Associated with Undiagnosed Stage 3 Chronic Kidney Disease. *Diabetes* 70 (2021).
44. Banerjee D, Wang AY. Personalising heart failure management in CKD patients. *Nephrol Dial Transplant* 2021.
45. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *N Engl J Med* 375 (2016): 1801-1802.
46. Perkovic V, Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2: results from the CANVAS Program randomised clinical trials. *Lancet Diabetes Endocrinol* 6 (2018): 691-704.
47. Mosenson O, Wiviott SD, Cahn A. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial. *Lancet Diabetes Endocrinol* 7 (2019): 606-617.
48. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. *N Engl J Med* 380 (2019): 2295-2306.
49. Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. *N Engl J Med* 384 (2021): 129-139.
50. Scheen AJ. An update on the safety of SGLT2 inhibitors. *Expert Opin Drug Saf* 18 (2019): 295-311.
51. Zelniker TA, Wiviott SD, Raz Im K, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *Lancet* 393 (2019): 31-39.
52. Nassif ME. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction The DEFINE-HF Trial. *Circulation* 140 (2019): 1463-1476.
53. Maddox TM, Januzzi JL, Allen LA, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. *J Am Coll Cardiol* 77 (2021): 772-810.
54. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. *Diabetes Care* 44 (2021): S111-24.
55. McDonald M, Virani S, Chan M, et al. CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. *Can J Cardiol* 37 (2021): 531-546.
56. Practical approach to SGLT2 inhibitors for treatment of cardiovascular disease. *Canadian Heart Failure Society* (2021).
57. Lam D, Shaikh A. Real-life prescribing of SGLT2 inhibitors: How to handle other medications, including glucose-lowering drugs and diuretics. *Kidney360*. 2 (2021).
58. Packer M, Butler J, Zannad F, et al. Effect of Empagliflozin on Worsening Heart Failure Events in Patients with Heart Failure and a Preserved Ejection Fraction: The EMPEROR-Preserved Trial. *Circulation* (2021).
59. Nassif ME, Qintar M, Windsor SL, et al. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial. *Circulation* 143 (2021): 1673-1686.
60. Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. *Nat Med* 27 (2021): 1954-1960.